Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab vs certolizumab pegol in active ankylosing spondylitis
2017-000957-37Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in ankylosing spondylitis (AS) (2 arms), sponsored by UCB. Primary endpoint: Change from baseline in ASDAS at Week 12. Started Jul 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2017-000957-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000957-37.